A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.

@article{Chi2012AP2,
  title={A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.},
  author={Kim N. Chi and Elaine Beardsley and Bernie J Eigl and Peter M. Venner and S{\'e}bastien J. Hotte and Eric William Winquist and Y-J Ko and Srikala S. Sridhar and Dirk Weber and Fred Saad},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 1},
  pages={53-8}
}
BACKGROUND The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. PATIENTS AND METHODS Eligible patients had progressive disease within 6 months of receiving docetaxel. Patupilone was administered 10 mg/m2 i.v. every 3 weeks. The primary end point was the proportion of patients with a confirmed≥50% prostate-specific antigen (PSA) decline. RESULTS Eighty-three patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study

  • WW ten Bokkel Huinink, J Sufliarsky, WM Smit
  • J Clin Oncol
  • 2009
1 Excerpt

: results from ASCENT , a double - blinded , randomized comparison of high - dose calcitriol plus docetaxel with placebo plus docetaxel

  • B Jankovic, E Beardsley, KN Chi
  • 2008

Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgenindependent prostate cancer (AIPC)

  • J Graff, DC Smith, L Neerukonda
  • J Clin Oncol
  • 2008
1 Excerpt

Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis

  • B Jankovic, E Beardsley, KN. Chi
  • 2008
1 Excerpt

patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone

  • J Graff, DC Smith, L Neerukonda
  • 2007

Similar Papers

Loading similar papers…